조직공학 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문별 예측(2025-2030년)

Tissue Engineering Market Size, Share & Trends Analysis Report By Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Orthopedics, Musculoskeletal, & Spine, Urology), By Region And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

조직공학 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 조직공학 시장 규모는 2030년까지 431억 3,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 14.3%의 성장률을 보일 것으로 예상됩니다.

심혈관질환, 당뇨병, 정형외과 질환과 같은 만성질환의 증가로 인해 손상된 조직을 복구하거나 대체하는 조직공학 솔루션에 대한 수요가 증가하고 있습니다. 생체재료, 3D 바이오프린팅, 줄기세포 연구, 유전자 편집 기술의 발전으로 조직공학 분야는 복잡하고 기능적인 조직을 개발할 수 있게 되었습니다.

동종 조직 이식법은 자가 이식의 사용 및 접근성과 관련된 문제점과 한계에 효과적으로 대응하고 있습니다. 또한, 동종 임플란트를 생체 임플란트로 전환하기 위한 임플란트 고정 및 멸균과 같은 특수 시술의 발전은 이 시장의 수익을 증가시킬 것으로 예상됩니다.

조직 재생 기술은 효과적인 제품과 낮은 거부 반응률로 인해 인기를 얻고 있으며, 재생 치료의 증가로 이어지고 있습니다. 전임상 연구는 현재 심혈관 수술 및 치료에 조직공학 인공 혈관을 사용하는 것에 초점을 맞추고 있습니다. 또한, 조직공학 방광은 현재 환자의 체외 이식에 성공적으로 적용되고 있습니다. 이러한 발전에도 불구하고, 높은 제품 개발 비용과 줄기세포 연구 및 조직공학 제품을 둘러싼 윤리적 문제 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

조직공학 시장 보고서 하이라이트

• 정형외과, 근골격계 및 척추 부문은 근골격계 질환의 유병률 증가로 인해 2024년 59.21%의 시장 점유율로 가장 큰 매출을 차지할 것으로 예상됩니다.
• 북미가 2024년 51.30%의 최대 매출 점유율을 차지하며 시장을 장악했습니다. 이는 줄기세포 치료에 대한 인식 증가, 노인 인구의 증가, 만성질환의 유병률 증가에 기인합니다.
• 아시아태평양 조직공학 시장은 시장 추정 및 예측 기간 동안 19.04%의 CAGR을 기록할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 조직공학 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 조직공학 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 용도 비즈니스 분석

• 부문 대시보드
• 세계의 조직공학 시장 용도 변동 분석
• 세계의 조직공학 시장 규모와 동향 분석, 용도별, 2018-2030년
• 제대혈과 세포은행
• 암
• 소화기과/부인과
• 치과
• 피부와 외피
• 비뇨기과
• 정형외과, 근골격, 척추
• 신경학
• 심혈관학
• 기타

제5장 지역 비즈니스 분석

• 지역 대시보드
• 조직공학 시장 : 지역별 점유율, 2024년 및 2030년
• 북미
  • 북미 조직공학 시장, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 조직공학 시장, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 노르웨이
  • 덴마크
• 아시아태평양
  • 아시아태평양의 조직공학 시장, 2018-2030년
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카의 조직공학 시장, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카 조직공학 시장, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제6장 경쟁 상황

• 기업/경쟁 분류
• 전략 매핑
• 2024년 기업 포지션 분석
• 기업 개요/리스트
  • Zimmer Biomet Holdings, Inc.
  • AbbVie(Allergan)
  • Becton, Dickinson and Company
  • B. Braun
  • Integra LifeSciences Corporation
  • Organogenesis Holdings Inc.
  • Medtronic
  • ACell, Inc.
  • Athersys, Inc.
  • Tissue Regenix Group plc
  • Stryker Corporation
  • RTI Surgical, Inc.
  • ReproCell, Inc.
  • Baxter International, Inc.

ksm

영문 목차

영문목차

Tissue Engineering Market Growth & Trends:

The global tissue engineering market size is estimated to reach USD 43.13 billion by 2030, growing at an estimated CAGR of 14.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of chronic diseases, such as cardiovascular diseases, diabetes, and orthopedic disorders, has driven the demand for tissue engineering solutions that can repair or replace damaged tissues. Advances in biomaterials, 3D bioprinting, stem cell research, and gene editing techniques have propelled the field of tissue engineering, enabling the development of complex and functional tissues.

The allogeneic tissue transplant method effectively addresses the challenges and limitations associated with the use and accessibility of autologous transplants. In addition, the advancement of specialized procedures, such as implant fixing and sterilization, aimed at converting allogeneic implants into biostatic implants, is anticipated to boost revenue generation in this market.

Tissue regeneration technology is gaining popularity due to its effective products and low rejection rates, leading to an increase in regeneration treatments. Pre-clinical research is currently focused on the use of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Moreover, tissue-engineered bladders can now be successfully implanted outside of the patient's body. Despite these advancements, the market's growth is hindered by challenges such as the high cost of product development and ethical concerns surrounding stem cell research and tissue-engineered products.

Tissue Engineering Market Report Highlights:

• The orthopedics, musculoskeletal, & spine segment held the largest revenue of 59.21% market share in 2024, owing to the increasing prevalence of musculoskeletal disorders.
• North America dominated the market and accounted for the largest revenue share of 51.30% in 2024, owing to rising awareness of stem cell therapy, the growing geriatric population, and the rising incidence of chronic diseases.
• The market for tissue engineering in Asia Pacific is estimated to witness the fastest CAGR of 19.04% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Application
  • 1.1.2. Regional scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Tissue Engineering Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in stem cell technology & tissue engineering
    • 3.2.1.2. Rise in number of clinical studies for Tissue Engineering and tissue engineering
    • 3.2.1.3. Increasing tissue engineering research funding
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of product development
    • 3.2.2.2. Ethical concerns related to stem cell research & tissue engineered product
    • 3.2.2.3. Clinical issues pertaining to development & implementation of stem cell therapies
• 3.3. Tissue Engineering Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Application Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Tissue Engineering Market Application Movement Analysis
• 4.3. Global Tissue Engineering Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
• 4.4. Cord blood & Cell banking
  • 4.4.1. Cord blood & Cell banking market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Cancer
  • 4.5.1. Cancer market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. GI/Gynecology
  • 4.6.1. GI/Gynecology therapy market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Dental
  • 4.7.1. Dental market estimates and forecast 2018 - 2030 (USD Million)
• 4.8. Skin & Integumentary
  • 4.8.1. Skin & Integumentary market estimates and forecast 2018 - 2030 (USD Million)
• 4.9. Urology
  • 4.9.1. Urology market estimates and forecast 2018 - 2030 (USD Million)
• 4.10. Orthopedics, Musculoskeletal, & Spine
  • 4.10.1. Orthopedics, Musculoskeletal, & Spine market estimates and forecast 2018 - 2030 (USD Million)
• 4.11. Neurology
  • 4.11.1. Neurology market estimates and forecast 2018 - 2030 (USD Million)
• 4.12. Cardiology & Vascular
  • 4.12.1. Cardiology & Vascular market estimates and forecast 2018 - 2030 (USD Million)
• 4.13. Others
  • 4.13.1. Others market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

• 5.1. Regional Dashboard
• 5.2. Tissue Engineering Market: Share By Region, 2024 & 2030
• 5.3. North America
  • 5.3.1. North America Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. U.S. Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Canada Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Mexico Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. Europe Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. UK Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Germany Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. France Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Italy Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Spain Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Sweden Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key Country Dynamics
    • 5.4.8.2. Competitive Scenario
    • 5.4.8.3. Regulatory Framework
    • 5.4.8.4. Norway Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.9. Denmark
    • 5.4.9.1. Key Country Dynamics
    • 5.4.9.2. Competitive Scenario
    • 5.4.9.3. Regulatory Framework
    • 5.4.9.4. Denmark Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Asia Pacific Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. China Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.5.3. Japan
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Japan Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. India Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Competitive Scenario
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Australia Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Competitive Scenario
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Thailand Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Competitive Scenario
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. South Korea Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Latin America Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Brazil Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Argentina Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. MEA Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.7.2. South Africa
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. South Africa Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.7.3. Saudi Arabia
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Competitive Scenario
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Saudi Arabia Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.7.4. UAE
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Competitive Scenario
    • 5.7.4.3. Regulatory Framework
    • 5.7.4.4. UAE Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Competitive Scenario
    • 5.7.5.3. Regulatory Framework
    • 5.7.5.4. Kuwait Tissue Engineering Testing Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Strategy Mapping
• 6.3. Company Position Analysis, 2024
• 6.4. Company Profiles/Listing
  • 6.4.1. Zimmer Biomet Holdings, Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. AbbVie (Allergan)
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Becton, Dickinson and Company
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. B. Braun
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Integra LifeSciences Corporation
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Organogenesis Holdings Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. Medtronic
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. ACell, Inc.
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. Athersys, Inc.
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Tissue Regenix Group plc
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives
  • 6.4.11. Stryker Corporation
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic Initiatives
  • 6.4.12. RTI Surgical, Inc.
    • 6.4.12.1. Overview
    • 6.4.12.2. Financial Performance
    • 6.4.12.3. Product Benchmarking
    • 6.4.12.4. Strategic Initiatives
  • 6.4.13. ReproCell, Inc.
    • 6.4.13.1. Overview
    • 6.4.13.2. Financial Performance
    • 6.4.13.3. Product Benchmarking
    • 6.4.13.4. Strategic Initiatives
  • 6.4.14. Baxter International, Inc.
    • 6.4.14.1. Overview
    • 6.4.14.2. Financial Performance
    • 6.4.14.3. Product Benchmarking
    • 6.4.14.4. Strategic Initiatives

관련자료